Skip to main content
logo
Pfizer Inc. (BKK:PFIZER19)
Thailand flag Thailand · Delayed Price · Currency is THB
16.80
+0.20 (1.20%)
Last updated: Mar 5, 2026, 2:10 PM ICT

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Primary Care Revenue
26.82B30.14B
Primary Care Revenue Growth
-11.00%-2.16%
Specialty Care Revenue
17.55B16.65B
Specialty Care Revenue Growth
5.37%11.10%
Oncology Revenue
16.83B15.61B
Oncology Revenue Growth
7.83%25.40%
Global Pharmaceuticals Business (Biopharma) Revenue
61.20B62.40B
Global Pharmaceuticals Business (Biopharma) Revenue Growth
-1.93%7.15%
Business Innovation (Pfizer CentreOne) Revenue
1.34B1.15B
Business Innovation (Pfizer CentreOne) Revenue Growth
16.75%-9.91%
Revenue (Other)
42.00M81.00M
Revenue (Total)
62.58B63.63B
Revenue (Total) Growth
-1.65%6.84%

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
United States Revenue
37.08B38.69B
United States Revenue Growth
-4.17%37.47%
Developed Markets Revenue
16.19B16.06B
Developed Markets Revenue Growth
0.82%-23.21%
Emerging Markets Revenue (Post-FY2023 Reporting)
9.31B8.88B
Emerging Markets Revenue (Post-FY2023 Reporting) Growth
4.89%-15.42%
Revenue (Total)
62.58B63.63B
Revenue (Total) Growth
-1.65%6.84%

Revenue by Geography 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
United States Revenue
37.08B38.69B
United States Revenue Growth
-4.17%37.47%
Revenue (Total)
62.58B63.63B
Revenue (Total) Growth
-1.65%6.84%

Revenue by Geography 3

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
United States Revenue
37.08B38.69B
United States Revenue Growth
-4.17%37.47%
International Revenue
25.50B24.94B
International Revenue Growth
2.27%-20.61%
Revenue (Total)
62.58B63.63B
Revenue (Total) Growth
-1.65%6.84%

EBT

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Global Pharmaceuticals Business (Biopharma) Earnings
29.34B27.97B
Global Pharmaceuticals Business (Biopharma) Earnings Growth
4.91%77.39%
Other Business Activities Earnings
-8.20B-7.21B

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Comirnaty Direct Sales and Alliance Revenue
4.37B5.35B
Comirnaty Direct Sales and Alliance Revenue Growth
-18.42%-52.29%
Eliquis Alliance Revenue and Direct Sales
7.96B7.37B
Eliquis Alliance Revenue and Direct Sales Growth
8.08%9.17%
Paxlovid Revenue
2.36B5.72B
Paxlovid Revenue Growth
-58.68%346.91%
Prevnar Family Revenue
6.49B6.41B
Prevnar Family Revenue Growth
1.29%-1.38%
Nurtec ODT/Vydura Revenue
1.42B1.26B
Nurtec ODT/Vydura Revenue Growth
12.75%36.10%
Abrysvo Revenue
1.03B755.00M
Abrysvo Revenue Growth
36.82%-15.17%
Vyndaqel Family Revenue
6.38B5.45B
Vyndaqel Family Revenue Growth
17.04%64.14%
Xeljanz Revenue
1.09B1.17B
Xeljanz Revenue Growth
-6.93%-31.41%
Ibrance Revenue
4.12B4.37B
Ibrance Revenue Growth
-5.61%-8.12%
Updated Dec 31, 2025. Data Source: Fiscal.ai.